These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 8183238)

  • 21. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
    Smeets RL; Fouraux MA; Pouwels W; van Emst-de Vries SE; Ronken E; De Pont JJ; Willems PH
    Br J Pharmacol; 1998 Jul; 124(5):935-45. PubMed ID: 9692779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells.
    Klueppelberg UG; Molero X; Barrett RW; Miller LJ
    Mol Pharmacol; 1990 Aug; 38(2):159-63. PubMed ID: 2200953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
    Stark HA; Sharp CM; Sutliff VE; Martinez J; Jensen RT; Gardner JD
    Biochim Biophys Acta; 1989 Feb; 1010(2):145-50. PubMed ID: 2463851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping.
    Vaughan RA
    Mol Pharmacol; 1995 May; 47(5):956-64. PubMed ID: 7746282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
    Lin CW; Miller T
    J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of crosslinkable and photolabile probes.
    Klueppelberg UG; Powers SP; Miller LJ
    Receptor; 1990-1991 Winter; 1(1-2):1-11. PubMed ID: 2152369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
    Anders J; Blüggel M; Meyer HE; Kühne R; ter Laak AM; Kojro E; Fahrenholz F
    Biochemistry; 1999 May; 38(19):6043-55. PubMed ID: 10320330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor.
    Pearson RK; Miller LJ; Hadac EM; Powers SP
    J Biol Chem; 1987 Oct; 262(28):13850-6. PubMed ID: 3654639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two functionally distinct cholecystokinin receptors show different modes of action on Ca2+ mobilization and phospholipid hydrolysis in isolated rat pancreatic acini. Studies using a new cholecystokinin analog, JMV-180.
    Matozaki T; Göke B; Tsunoda Y; Rodriguez M; Martinez J; Williams JA
    J Biol Chem; 1990 Apr; 265(11):6247-54. PubMed ID: 1690723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
    Sarri E; Ramos B; Salido GM; Claro E
    Br J Pharmacol; 2001 Aug; 133(8):1227-34. PubMed ID: 11498507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches.
    Miller LJ
    Yale J Biol Med; 1992; 65(5):441-8; discussion 465-9. PubMed ID: 1340061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding.
    Piersen CE; True CD; Wells JN
    Mol Pharmacol; 1994 May; 45(5):861-70. PubMed ID: 8190103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells.
    Dawra R; Saluja A; Lerch MM; Saluja M; Logsdon C; Steer M
    Biochem Biophys Res Commun; 1993 Jun; 193(3):814-20. PubMed ID: 8323557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biochemical characterization of a subtype pancreatic cholecystokinin receptor and of its agonist binding domain.
    Poirot SS; Dufresne M; Jiménez J; Vaysse N; Fourmy D
    J Recept Res; 1992; 12(2):233-53. PubMed ID: 1583623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
    Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
    J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The gall bladder cholecystokinin receptor exists in two guanine nucleotide-binding protein-regulated affinity states.
    Molero X; Miller LJ
    Mol Pharmacol; 1991 Feb; 39(2):150-6. PubMed ID: 1899903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.